Keyphrases
Acute Inflammation
10%
Antibody Targeting
10%
Antibody Therapy
10%
Autoimmune Disease
10%
Biological Therapy
20%
BioRxiv
10%
Citrobacter Rodentium
10%
Clinical Samples
10%
Clinical Setting
10%
Colonic mucus
20%
Commensal
10%
Commensal Gut Bacteria
10%
Commensal Microorganisms
10%
Degrading Bacteria
20%
Deprivation
10%
Developed Countries
10%
Diet Therapy
10%
Dietary Fiber
20%
Disease Groups
10%
Dysregulated
10%
Enteropathogenic Infection
20%
Fiber Intake
10%
Gastrointestinal Tract
10%
Glycan Degradation
20%
Gut Microbial Community
10%
Gut Microbiome
30%
Gut Microbiota
20%
High-throughput Culturing
20%
Host Immune Response
10%
Immune Profiling
10%
Immune Response
10%
Industry Settings
20%
Inflammatory Bowel Disease
40%
Inflammatory Bowel Disease Treatment
20%
Infliximab
10%
Intestinal Bacterial Community
10%
Intestinal mucosa
20%
Luxembourg
10%
Medical Treatment
10%
Microbial Contribution
10%
Microbiome
10%
Microbiota
10%
Moderate Disease
10%
Mucin
40%
Mucin Glycans
20%
Mucin-degrading Bacteria
50%
Mucosal Immune Response
10%
Mucosal Pathogens
10%
Mucus Barrier
10%
Mucus Layer
10%
Mucus Thickness
20%
Newly Diagnosed
10%
Nutritional Habits
10%
Omics Analysis
10%
Overgrowth
10%
Pathogen Susceptibility
10%
Pathogenic Microorganisms
10%
Patient Blood Samples
10%
Patient Cohort
10%
PhD Project
10%
PhD Students
20%
Sample Cutting
20%
Sample Throughput
10%
Severe Disease
10%
Special Diets
10%
Specific Pathogen Free Mice
10%
T Cell Homing
10%
Translational Approach
50%
Ulcerative Colitis
50%
Ulcerative Colitis Patient
40%
Vedolizumab
20%
Immunology and Microbiology
Acute Inflammation
11%
Autoimmune Disease
11%
Cell Homing
11%
Citrobacter Rodentium
11%
Commensal
11%
Gastrointestinal Tract
11%
Germfree Mouse
11%
Glycan
22%
Gut Microbiome
22%
Host Immune Response
11%
Immune Response
11%
Immunocompetent Cell
11%
Infectious Agent
22%
Inflammatory Bowel Disease
55%
Infliximab
11%
Intestine Flora
33%
Microbiome
11%
Microflora
11%
Microorganism
22%
Mucin
100%
Mucosal Immune Response
11%
T Cell
11%
Tumor Necrosis Factor
11%
Ulcerative Colitis
100%
Vedolizumab
11%